Jason’s career began as a chemist in the pharmaceutical industry and evolved into a product and marketing manager with Schering-Plough in Japan. Upon returning from Japan, Jason joined Salomon Smith Barney, as a research associate which has now evolved into a 20-year career on Wall Street as a leader in the Healthcare space.

Jason will leverage his unique and diversified experiences to work across the Dawson James platform to augment the research product focusing on small and middle capitalized emerging growth companies utilizing Dawson James’ “Diversified Investor Offering™”, building their shareholder base with a combination of retail and institutional accounts.

Jason’s coverage will be across multiple therapeutic areas in biotechnology, specialty pharmaceuticals, and medical devices. As an analyst Jason has developed a high level of expertise in oncology, virology and cell-based medicine such as CAR (Chimeric Antigen Receptor)-T cells and regenerative medicine (stem cells).

Mr. Kolbert spent the last year as a senior biotechnology analyst at HC Wainwright and previously seven years at the Maxim group, where he was an Executive Managing Director and the Head of Healthcare at the firm. During this period Jason and his team covered 80 names across the healthcare vertical. Jason’s Wall Street career began with seven years at Citi Group followed by several years on the buy side as a portfolio manager with the Susquehanna International Group. Mr. Kolbert returned to his sell-side role after spending time in Industry as the head of business development for a public cell therapy company. Mr. Kolbert holds an undergraduate degree from the State University of New York in Chemistry and a Master’s in Business Administration from the University of New Haven.